Collegium Pharmaceutical, Inc. Amortization of Intangible Assets
Collegium Pharmaceutical, Inc. (COLL) reported Amortization of Intangible Assets of $62.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $62.95M, a 13.48% increase year-over-year.
- Collegium Pharmaceutical, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $55.47M, a 0.00% change year-over-year.
- Collegium Pharmaceutical, Inc. amortization of intangible assets for the quarter ending 2025-06-30 was $55.47M, a 60.72% increase year-over-year.
- Collegium Pharmaceutical, Inc. amortization of intangible assets for the quarter ending 2025-03-31 was $55.47M, a 60.71% increase year-over-year.
- Collegium Pharmaceutical, Inc. amortization of intangible assets for fiscal 2025 was $221.89M, a 34.23% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. amortization of intangible assets for fiscal 2024 was $165.30M, a 13.41% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. amortization of intangible assets for fiscal 2023 was $145.76M.
- Collegium Pharmaceutical, Inc. amortization of intangible assets for fiscal 2021 was $67.18M, a 10.71% increase from fiscal 2020.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 26 month |
|---|---|---|---|---|---|
| 2026-06-30 | $62.95M 10-Q · filed 2026-08-06 | $118.43M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $55.47M 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $221.89M 10-K · filed 2026-02-26 | ||||
| 2025-06-30 | $55.47M 10-Q · filed 2026-08-06 | $110.95M 10-Q · filed 2026-08-06 | $166.42M derived: sum of 3 quarters · filed 2026-08-06 | $207.22M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $55.47M 10-Q · filed 2026-05-07 | $110.94M derived: sum of 2 quarters · filed 2026-05-07 | $151.75M derived: sum of 3 quarters · filed 2026-05-07 | $186.26M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $55.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $96.27M derived: sum of 2 quarters · filed 2026-02-26 | $130.79M derived: sum of 3 quarters · filed 2026-02-26 | $165.30M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $40.80M 10-Q · filed 2024-11-07 | $75.32M derived: sum of 2 quarters · filed 2024-11-07 | $109.83M 10-Q · filed 2024-11-07 | $144.35M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $34.52M 10-Q · filed 2024-08-08 | $69.03M 10-Q · filed 2024-08-08 | $103.55M derived: sum of 3 quarters · filed 2026-02-26 | $139.86M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $34.52M 10-Q · filed 2024-05-09 | $69.03M derived: sum of 2 quarters · filed 2026-02-26 | $105.35M derived: sum of 3 quarters · filed 2026-02-26 | $142.81M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $34.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $70.83M derived: sum of 2 quarters · filed 2026-02-26 | $108.29M derived: sum of 3 quarters · filed 2026-02-26 | $145.76M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $36.32M 10-Q · filed 2024-11-07 | $73.78M derived: sum of 2 quarters · filed 2024-11-07 | $111.25M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $37.46M 10-Q · filed 2024-08-08 | $74.93M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $37.47M 10-Q · filed 2024-05-09 | ||||
| 2022-09-30 | $37.55M 10-Q · filed 2023-11-07 | $75.05M derived: sum of 2 quarters · filed 2023-11-07 | $93.98M 10-Q · filed 2023-11-07 | $110.77M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $37.50M 10-Q · filed 2023-08-03 | $56.42M 10-Q · filed 2023-08-03 | $73.22M derived: sum of 3 quarters · filed 2023-08-03 | $90.02M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $18.92M 10-Q · filed 2023-05-04 | $35.72M derived: sum of 2 quarters · filed 2023-05-04 | $52.51M derived: sum of 3 quarters · filed 2023-05-04 | $69.31M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $16.80M 10-K · filed 2022-02-24 | $33.59M derived: sum of 2 quarters · filed 2022-11-03 | $50.39M derived: sum of 3 quarters · filed 2022-11-03 | $67.18M 10-K · filed 2022-02-24 | |
| 2021-09-30 | $16.80M 10-Q · filed 2022-11-03 | $33.59M derived: sum of 2 quarters · filed 2022-11-03 | $50.39M 10-Q · filed 2022-11-03 | $67.18M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $16.80M 10-Q · filed 2022-08-04 | $33.59M 10-Q · filed 2022-08-04 | $50.38M derived: sum of 3 quarters · filed 2022-08-04 | $67.18M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $16.80M 10-Q · filed 2022-05-10 | $33.59M derived: sum of 2 quarters · filed 2022-05-10 | $50.38M derived: sum of 3 quarters · filed 2022-05-10 | $67.18M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $16.80M 10-K · filed 2022-02-24 | $33.59M derived: sum of 2 quarters · filed 2022-02-24 | $50.38M derived: sum of 3 quarters · filed 2022-02-24 | $60.68M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $16.80M 10-K · filed 2022-02-24 | $33.59M derived: sum of 2 quarters · filed 2022-02-24 | $43.88M 10-Q · filed 2021-11-04 | $47.57M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $16.80M 10-K · filed 2022-02-24 | $27.09M 10-Q · filed 2021-08-05 | $30.78M derived: sum of 3 quarters · filed 2022-02-24 | $34.47M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $10.29M 10-K · filed 2022-02-24 | $13.98M derived: sum of 2 quarters · filed 2022-02-24 | $17.67M derived: sum of 3 quarters · filed 2022-02-24 | $21.36M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-02-29 | $126.34M 10-Q · filed 2020-11-05 | ||||
| 2019-12-31 | $3.69M 10-K · filed 2021-02-25 | $7.38M derived: sum of 2 quarters · filed 2021-02-25 | $11.06M derived: sum of 3 quarters · filed 2021-02-25 | $14.75M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $3.69M 10-K · filed 2021-02-25 | $7.38M derived: sum of 2 quarters · filed 2021-02-25 | $11.06M 10-Q · filed 2020-11-05 | $26.56M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $3.69M 10-K · filed 2021-02-25 | $7.38M 10-Q · filed 2020-08-05 | $22.87M derived: sum of 3 quarters · filed 2021-02-25 | $55.28M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $3.69M 10-K · filed 2021-02-25 | $19.18M derived: sum of 2 quarters · filed 2021-02-25 | $51.59M derived: sum of 3 quarters · filed 2021-02-25 | $84.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $15.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $47.90M derived: sum of 2 quarters · filed 2021-02-25 | $80.31M derived: sum of 3 quarters · filed 2021-02-25 | $109.83M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $32.41M 10-Q · filed 2019-11-06 | $64.81M derived: sum of 2 quarters · filed 2019-11-06 | $94.34M 10-Q · filed 2019-11-06 | $94.37M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-06-30 | $32.41M 10-Q · filed 2019-08-07 | $61.93M 10-Q · filed 2019-08-07 | $61.97M derived: sum of 3 quarters · filed 2019-08-07 | $62.01M derived: sum of 4 quarters · filed 2019-08-07 | |
| 2018-03-31 | $29.53M 10-Q · filed 2019-05-08 | $29.56M derived: sum of 2 quarters · filed 2019-05-08 | $29.61M derived: sum of 3 quarters · filed 2019-05-08 | $29.65M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $81.00K derived: sum of 2 quarters · filed 2019-02-27 | $128.00K derived: sum of 3 quarters · filed 2019-02-27 | $258.00K 10-K · filed 2019-02-27 | |
| 2017-09-30 | $48.00K 10-Q · filed 2018-11-08 | $95.00K derived: sum of 2 quarters · filed 2018-11-08 | $225.00K 10-Q · filed 2018-11-08 | $395.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $47.00K 10-Q · filed 2018-08-08 | $177.00K 10-Q · filed 2018-08-08 | $347.00K derived: sum of 3 quarters · filed 2019-02-27 | $574.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $130.00K 10-Q · filed 2018-05-09 | $300.00K derived: sum of 2 quarters · filed 2019-02-27 | $527.00K derived: sum of 3 quarters · filed 2019-02-27 | $527.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $397.00K derived: sum of 2 quarters · filed 2019-02-27 | $397.00K derived: sum of 3 quarters · filed 2019-02-27 | $397.00K 10-K · filed 2019-02-27 | |
| 2016-09-30 | $227.00K 10-Q · filed 2017-11-08 | $227.00K derived: sum of 2 quarters · filed 2017-11-08 | $227.00K 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |